See today's BioWorld Science
To read the full story, subscribe or sign in.
Endocrine/metabolic

PL-7737 gets orphan drug status for leptin receptor deficiency

March 26, 2025
Palatin Technologies Inc. has obtained U.S. orphan drug designation for PL-7737 for leptin receptor (LEPR) deficiency, including obesity caused by this condition.
BioWorld Science Regulatory Endocrine/metabolic FDA Orphan drug